Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 1/2 1

Status

Unknown 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 5NIH 4OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 23Thoracic 19Breast 11Gynecologic 7Tumor-Agnostic 5Head & Neck 4Dermatologic 4Other solid neoplasm 3Genitourinary 3Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Endocrine 1CNS 1

Conditions

Neoplasms 4Neoplasm Metastasis 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Taxes × Tumor-Agnostic × Clear all
NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Merck Sharp & Dohme LLC

Phase 1 Completed
470 enrolled
Tumor-Agnostic

Neoplasms

NCT03918278 2025-06-25

MK-0482-001

Merck Sharp & Dohme LLC

Phase 1 Completed
222 enrolled
Tumor-Agnostic

Neoplasms

NCT04033354 2023-08-08

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Shanghai Henlius Biotech

Phase 3 Unknown
537 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04652206 2021-12-29

PANTAX-Ib

Scandion Oncology A/S

Phase 1/2 Unknown
18 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡